Send to

Choose Destination
J Clin Endocrinol Metab. 2019 Aug 7. pii: jc.2019-01081. doi: 10.1210/jc.2019-01081. [Epub ahead of print]

Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in obese, non-diabetic men.

Author information

Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Medical Research Laboratory, Department of Clinical Medicine, Aarhus University Hospital, Denmark.
Department of Clinical Pharmacology, Aarhus University Hospital, Denmark.
Department of Biomedical Sciences, Section for Translational Metabolic Physiology, University of Copenhagen, Denmark.
Department of Endocrinology, Aarhus University Hospital, Denmark.
Department of Biomedicine, Aarhus University, Denmark.
Steno Diabetes Center Aarhus, Aarhus University Hospital, Denmark.



Augmenting NAD+ metabolism through dietary provision of NAD+ precursor vitamins translate to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We aimed to test if NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acids levels in humans.


A 12-week randomized, double-blind, placebo-controlled, and parallel-group trial in 40 obese, insulin-resistant males allocated to NR 1,000 mg twice daily (n = 20) or placebo (n = 20).


2-hour 75 gram oral glucose tolerance tests (OGTT) were performed before and after the intervention and plasma concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, and GIP were determined. β-cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined.


NR supplementation during 12 weeks neither affected fasting nor post-glucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. In addition, no changes in circulating adipsin or bile acids were observed following NR supplementation.


The present study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in obese, non-diabetic males. Moreover, bile acid levels in plasma did not change in response to NR supplementation.


Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center